Αρχική World News No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy... World News No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer Από Ogkologos - 24 Μαρτίου, 2025 1003 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not... 8 Απριλίου, 2025 Cancer Patients Get Free, Beautiful Henna Crowns From Local Artist 17 Μαρτίου, 2020 Two Early Studies Show Rapid Antitumour CAR-Mediated Responses, but Often of... 20 Μαρτίου, 2024 R2-ISS: an Improved and Simple Prognostic Staging System Allows Better Stratification... 1 Ιουνίου, 2022 Φόρτωση περισσοτέρων HOT NEWS On World Cancer Day, ESMO Renews a Longstanding Commitment to Closing... ¿Puede el uso de aceites esenciales ayudar a tratar el cáncer... Women with Diabetes Less Likely to Opt into Cancer Screening, Despite... Black Women Have Nearly Three Times the Risk of Developing Triple...